Is Galderma's New Restylane Lyft Data and FDA Approval Reshaping Its Competitive Edge (SWX:GALD)?

• Galderma recently presented new clinical data from its Restylane and Sculptra portfolios at the American Society for Dermatologic Surgery 2025 Annual Meeting in Chicago, including results that supported the recent FDA approval of Restylane Lyft for chin augmentation in adults.
• This new data not only highlights high patient satisfaction and durable results for the company’s injectable aesthetics but also addresses emerging needs among patients experiencing facial changes following medication-driven weight loss.
• We'll review how Galderma’s expanded clinical evidence and FDA approval for Restylane Lyft may strengthen its competitive position in aesthetic medicine.

Outshine the giants: these 27 early-stage AI stocks could fund your retirement.

Galderma Group Investment Narrative Recap

To be a Galderma shareholder, you need to believe in the long-term expansion of the global aesthetics and dermatology market, fuelled by innovation and clinical leadership. The recent presentation of new Restylane and Sculptra data, including FDA approval for chin augmentation, may help mitigate short-term demand softness in injectables, but price competition remains the biggest near-term risk for the business, while uptake of new launches remains a key catalyst.

The FDA’s November 2025 approval of Restylane Lyft for chin augmentation stands out as the most relevant recent event, tying directly to the new clinical data shared at the ASDS meeting. This approval supports Galderma’s position in premium injectable aesthetics, while also offering additional growth opportunity if the expanded guidance for 2025 sales is met, especially as the company pushes further into the U.S. and global markets.

However, against this backdrop of innovation, investors should not overlook the impact of relentless price competition and changing consumer trends in the filler market ...

Read the full narrative on Galderma Group (it's free!)

Galderma Group's outlook forecasts $7.2 billion in revenue and $1.3 billion in earnings by 2028. This implies an annual revenue growth rate of 15.3%, with earnings rising by about $922 million from the current $378 million.

Uncover how Galderma Group's forecasts yield a CHF150.37 fair value, in line with its current price.

Exploring Other Perspectives

Simply Wall St Community members provided five fair value estimates for Galderma, ranging from CHF124.90 to CHF220.05. With clinical advances supporting product uptake, you can see how interpretations of demand and margin risk lead to wide differences, explore several analyses to inform your view.

Explore 5 other fair value estimates on Galderma Group - why the stock might be worth 15% less than the current price!

Build Your Own Galderma Group Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Galderma Group research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Galderma Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Galderma Group's overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Rare earth metals are the new gold rush. Find out which 37 stocks are leading the charge.
• Find companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com